Thrombus Precursor Protein as a Measure of Prothrombotic Activity in a Patient with Factor VIII Inhibitor Treated with Activated Prothrombin Complex Concentrates

• References

• 1 Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291: 164-7.
• 2 Hilgartner MW, Knatterud G. and the FEIBA Study Group. The use of factor-eight-inhibitor-by passing-activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36
• 3 Chavin I S, Siegel DM, Rocco TM, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 245-9.
• 4 White GC, Roberts HR, Kingdon HS, Lundbald RL. Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-70.
• 5 Hellstern P, Kôhler M. Prothrombin complex concentrates (PCC) and thromboembolic complications (Abstract). Ann Haematol 1995; 70 (Suppl. 01) A88
• 6 Francis CW, Conaghan DG, Scott WL, Marder VJ. Increased plasma concentrations of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75: 1170-6.